In this issue:
Biomarkers of response to T-DXd in advanced gastric cancer
Osimertinib consolidation prolongs PFS in unresectable EGFR-mutated NSCLC
Front-line chemo + molecularly guided therapy for unfavourable CUP
Stopping front-line pembrolizumab for NSCLC after two years is safe
Do NCCN recommendations for genome targeted therapies align with expected clinical value?
GLP-1RAs linked to reduced risk of obesity-related cancers
ctDNA-guided de-escalation targeted therapy for advanced NSCLC
Single-agent nivolumab beneficial after irAEs to nivolumab combo in melanoma
OPTICAL: Neoadjuvant chemotherapy feasible for locally advanced colon cancer
Sacituzumab fails to best docetaxel in previously treated NSCLC
Please login below to download this issue (PDF)